ResMed Inc.

ResMed's RSI of 26.6 signals deeply oversold conditions, yet the stock trades at a reasonable 19.7x earnings with a $33.3B market cap—suggesting the selloff may have outpaced fundamental deterioration. The medical device name sits well below its 52-week high, creating a potential setup where either capitulation-driven washout could attract value hunters, or the low RSI could represent genuine deterioration in demand for respiratory and cloud-connected care solutions that justifies further repricing downward. This gap between technicals and valuation warrants close monitoring of upcoming guidance and utilization trends.